KRAS and familial pancreatic carcinoma: Several research teams generated genetically engineered mouse models that express gain-of-function mutations of GNAS (R201H and R201C) to address the biological significance of GNAS alone or in combination with oncogenic KRAS in the formation of precursor lesions as well as the progression and maintenance of pancreatic cancer [139–141].